Plan B launches “strong”
This article was originally published in The Tan Sheet
Executive Summary
Barr Pharmaceuticals says "strong sales" of Plan B emergency contraceptive following its November launch contributed to a 22% increase in sales of the firm's proprietary products during its fiscal 2007 second quarter. In a Feb. 28 earnings call, the company said proprietary product sales for the October-December period increased $17 million from the year-ago period to $98 million. The firm declined to provide Plan B sales details, but Chairman and CEO Bruce Downey said the product "is up substantially ... year over year as a result of the OTC switch." Downey said Barr's three-year exclusivity for Plan B began with its launch, but the firm is "evaluating the options that we have for protecting that franchise beyond" its patents (1"The Tan Sheet," Nov. 13, 2006, p. 8)...